Physical disorder

Hoag Receives $50 Million Gift to Create One-of-a-Kind Center for Brain Health

Retrieved on: 
Monday, November 6, 2023
Diabetes, Deficit spending, News, Partnership, Hospital, Agitation, Memory, Mental health, Physician, Acquisition, Dementia, Leg, Caregiver, Medicine, Neuroscience, Parkinson's disease, Ron, Cancer, Patient, U.S. News & World Report, Golf, Alzheimer's disease, Ageing, DSM-IV codes, Research, Quality of life, Brain, Eagle Four, Depression, Anxiety, Physical disorder, Emotional and behavioral disorders, Education, Family, Friends, Trust, Newport, Diagnosis, Cognition, Myenteric plexus, Pharmaceutical industry, Nursing, Residential care, Medical imaging, Pickup, Neurosurgery, Neurology

NEWPORT BEACH, Calif., Nov. 6, 2023 /PRNewswire/ -- Hoag today announced a transformational $50 million gift that will establish the Richard H. Pickup Center for Brain Health, a powerhouse of innovation that will pioneer new, whole family-centered approaches to brain health and healthy aging.

Key Points: 
  • This gift will establish the Richard H. Pickup Center for Brain Health.
  • Cognitive and mental health disorders in seniors impair general health maintenance, predisposing them to repeat hospitalizations for physical disorders.
  • NEWPORT BEACH, Calif., Nov. 6, 2023 /PRNewswire/ -- Hoag today announced a transformational $50 million gift that will establish the Richard H. Pickup Center for Brain Health, a powerhouse of innovation that will pioneer new, whole family-centered approaches to brain health and healthy aging.
  • This latest multi-year gift will revolutionize the advancement of brain health care and treatment for people in Orange County and beyond.

Hopper Health Taps Violet to Deliver Culturally Competent Care for Neurodivergent Adults

Retrieved on: 
Thursday, April 27, 2023
Benchmark, Learning, Communication, Partnership, Education, OCD, Chronic pain, Physical disorder, Health equity, ADHD, Tourette syndrome, Disability studies, Spectrum, Patient, BIPOC, Nursing, Hopper, Violet

NEW YORK, April 27, 2023 /PRNewswire/ -- Hopper Health , a digital-first personalized primary care platform for neurodivergent adults, today announced it has partnered with Violet , the first health equity platform, to deliver more inclusive care at scale.

Key Points: 
  • NEW YORK, April 27, 2023 /PRNewswire/ -- Hopper Health , a digital-first personalized primary care platform for neurodivergent adults, today announced it has partnered with Violet , the first health equity platform, to deliver more inclusive care at scale.
  • Our partnership with Violet will empower Hopper clinicians to deliver more equitable and culturally-competent care to our patients."
  • Building a culturally competent system can help improve health outcomes and quality of care, can contribute to the elimination of racial and ethnic health disparities, and save billions in excess care spend .
  • "We are proud to partner with Hopper to enhance the communication and delivery of equitable care to neurodivergent adults."

BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Phoenix, Arizona

Retrieved on: 
Friday, December 2, 2022
IND, Neuro, COVID-19, Mental health, Neuropathic pain, Degenerative disease, Lysergic acid diethylamide, Disorder, Anxiety, Post-traumatic stress disorder, Research, Conference, Physical disorder, Depression, LSD, Patent, CSE, Pharmaceutical industry, Phoenix, Neuroscience

Dr. Aguilar-Valles will present preclinical data supporting the acute and long-term anti-depressant activity of BETR-001 monotherapy in animal models.

Key Points: 
  • Dr. Aguilar-Valles will present preclinical data supporting the acute and long-term anti-depressant activity of BETR-001 monotherapy in animal models.
  • Furthermore, the data shows that BETR-001 promotes structural neuroplasticity in brain neurons and this effect is partly mediated by the activation of 5-HT2A receptor.
  • BetterLife also owns a drug candidate for the treatment of viral infections such as COVID-19 and other respiratory viral infections.
  • The department has an interdisciplinary approach to understanding the emergence, prevention and treatment of mental and physical disorders.

atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression

Retrieved on: 
Tuesday, October 25, 2022
U.S. Securities and Exchange Commission, Perception, Time, Failure, Neuroscience, NASDAQ, RAAD, Patient, Physical disorder, Mental health, Anxiety, Private Securities Litigation Reform Act, Addiction, Ketamine, GLOBE, Annual report, Depression, Infection, NEW, Forward-looking statement, COVID-19, TRD, MADRS, Quality of life, MD, Suicidal ideation, List of life sciences, Entrepreneurship, Research, NMDA, CEO, Lists of diseases, Safety, Achievement, Program, SEC, Public expenditure, Intellectual property, Modified, Approximation error, Therapy, Security (finance), Neuropsychiatric Disease and Treatment, Â, Pharmaceutical industry

Completed enrollment of Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled clinical trial of PCN-101 (R-ketamine).

Key Points: 
  • Completed enrollment of Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled clinical trial of PCN-101 (R-ketamine).
  • atai to contextualize the upcoming Phase 2a topline results at its R&D Day today at 12 pm E.T.
  • The Phase 2a proof-of-concept trial is a randomized, double-blind, placebo-controlled study with an enrollment target of 93 TRD patients across three arms.
  • atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.

BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies

Retrieved on: 
Wednesday, July 6, 2022
Department, Headache, Neuro, Anxiety, Research, University, Investigational New Drug, Physical disorder, GLOBE, Lists of diseases, Carleton University, COVID-19, Hallucination, CSE, Post-traumatic stress disorder, Degenerative disease, Depression, Private sector, Mitacs, LSD, Principal, IND, Disorder, Organization, MOA, Lysergic acid diethylamide, Patent, Mental health, Postdoctoral researcher, Pharmaceutical industry

"BETR-001 is a potential novel therapy to treat debilitating psychiatric disorders with high unmet need, such as treatment-resistant severe depression and cluster headaches.

Key Points: 
  • "BETR-001 is a potential novel therapy to treat debilitating psychiatric disorders with high unmet need, such as treatment-resistant severe depression and cluster headaches.
  • BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark.
  • Carleton Neuroscience has an international reputation for research on stress and its effects on brain functioning and mental health.
  • Mitacs is a national, not-for-profit organization that has designed and delivered research and training programs in Canada for 20 years.

BetterLife To Present BETR-001 Preclinical Data at the Upcoming Federation of European Neuroscience Societies (FENS) Forum

Retrieved on: 
Tuesday, June 21, 2022
Patent, Carleton, Headache, COVID-19, Anxiety, Lists of diseases, Neuro, Depression, Research, Mental health, CSE, LSD, Post-traumatic stress disorder, Lysergic acid diethylamide, IND, Degenerative disease, Disorder, GLOBE, Physical disorder, Pharmaceutical industry, Neuroscience

The study, led by Dr. Vern Lewis, is part of BetterLifes collaboration with the laboratory of Dr. Argel Aguilar-Valles at Carleton Universitys Department of Neuroscience.

Key Points: 
  • The study, led by Dr. Vern Lewis, is part of BetterLifes collaboration with the laboratory of Dr. Argel Aguilar-Valles at Carleton Universitys Department of Neuroscience.
  • Dr. Lewis will present preclinical data demonstrating the anti-depressant and neural plasticity-promoting properties of BETR-001 from both in vitro and in vivo studies.
  • BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark.
  • The department has an interdisciplinary approach to understanding the emergence, prevention and treatment of mental and physical disorders.

IASO Biotherapeutics' Equecabtagene Autoleucel, the World's First CAR-T for Treatment of NMOSD, Receives IND Application Acceptance by NMPA

Retrieved on: 
Saturday, May 28, 2022
Serum, National Medical Products Administration, Neuromyelitis optica spectrum disorder, Center for Drug Evaluation and Research, B-ALL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, IIT, Aquaporin, Degenerative disease, Patient, Woman, Quality of life, Severe cognitive impairment, Visual acuity, Expanded Disability Status Scale, Paralysis, End organ damage, Lymphatic system, NMO, Hope, FDA, SAN, Nervous system, IND, Industry, CDE, Center, EDSS, Human, Defecation, Physical disorder, NMPA, Safety, CRS, Central nervous system, PD, Animal, CAR, BCMA, Prevalence, CD19, Visual impairment, Frost & Sullivan, Growth, ODD, Pharmaceutical industry, Vaccine, NMOSD

This NMPA acceptance, the world's first IND application for CAR-T in NMOSD.

Key Points: 
  • This NMPA acceptance, the world's first IND application for CAR-T in NMOSD.
  • IASO Bio's IND application is based on the Equecabtagene AutoleucelInvestigator Initiated Trial (IIT) enrolling patients with refractory NMOSD who were positive for Aquaporin 4 antibodies (AQP4).
  • Subjects enrolled were patients with poor symptom control despite at least one year of treatment with at least one immunosuppressant.
  • "Theuse of CAR-T cell products has been widely accepted in the treatment of hematologic malignancy but has been rarely reported in the treatment of autoimmune diseases.

BetterLife To Present BETR-001 Preclinical Data at the Upcoming Canadian Association for Neuroscience Conference

Retrieved on: 
Thursday, April 21, 2022
CSE, Patent, Carleton, Canadian Association for HIV Research, IND, Association, COVID-19, Research, Anxiety, Neuron, Post-traumatic stress disorder, LSD, GLOBE, Mitacs, Growth, Conference, Mental health, Physical disorder, Depression, Degenerative disease, Ketamine, Disorder, Neuro, Lists of diseases, Headache, Pharmaceutical industry, Neuroscience

The study, led by Dr. Vern Lewis, is part of BetterLifes collaboration with the laboratory of Dr. Argel Aguilar-Valles at Carleton Universitys Department of Neuroscience.

Key Points: 
  • The study, led by Dr. Vern Lewis, is part of BetterLifes collaboration with the laboratory of Dr. Argel Aguilar-Valles at Carleton Universitys Department of Neuroscience.
  • At CAN, Dr. Lewis will present preclinical data demonstrating the neural plasticity-promoting and anti-depressant properties of BETR-001 from both in vitro and in vivo studies.
  • BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark.
  • Carleton Neuroscience has an international reputation for research on stress and its effects on brain functioning and mental health.

BetterLife’s BETR-001 Demonstrates BETR-001 Anti-depressant Activity in Preclinical Models of Depression

Retrieved on: 
Wednesday, April 6, 2022
Physical disorder, Degenerative disease, Proactivity, Patent, Mental health, Post-traumatic stress disorder, Neuro, Mouse, IND, Lysergic acid diethylamide, Research, Hallucination, LSD, Interview, COVID-19, Lists of diseases, Disorder, GLOBE, Anxiety, Depression, Headache, CSE, Pharmaceutical industry

The study is part of BetterLifes collaboration with the laboratory of Dr. Argel Aguilar-Valles at Carleton Universitys (Carleton) Department of Neuroscience.

Key Points: 
  • The study is part of BetterLifes collaboration with the laboratory of Dr. Argel Aguilar-Valles at Carleton Universitys (Carleton) Department of Neuroscience.
  • The current study evaluated the anti-depressant activity of BETR-001 on depressive-like behavior of mice in a forced swim test.
  • The mounting evidence on BETR-001 efficacy in preclinical models of depression leaves little doubt on its therapeutic potential in depression and related disorders, stated BetterLifes Chief Executive Officer,Dr.
  • BetterLife is also pleased to present an interview by Dr. Doroudian with Proactive Investors discussing the anti-depressant activity of BETR-001.

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity in Preclinical Model

Retrieved on: 
Tuesday, February 15, 2022
Depression, Brain, Physical disorder, Neuron, LSD, IND, Anxiety, Prefrontal cortex, Degenerative disease, Hallucination, Mental health, Headache, Disorder, Lysergic acid diethylamide, Ketamine, Post-traumatic stress disorder, Neuro, Patent, CSE, Growth, Research, COVID-19, Atrophy, GLOBE, Pharmaceutical industry

Increased structural plasticity in the brain neurons (mainly prefrontal cortex) has been linked to the sustained antidepressant effects of ketamine and other psychedelic compounds.

Key Points: 
  • Increased structural plasticity in the brain neurons (mainly prefrontal cortex) has been linked to the sustained antidepressant effects of ketamine and other psychedelic compounds.
  • BetterLife had previously shown the anti-depressant properties of BETR-001 in a rodent chronic variable stress model.
  • In certain measurements of structural plasticity in neurons, BETR-001 performs better than ketamine in this model.
  • Dr. Argel Aguilar-Valles commented, We are pleased to collaborate with the BetterLife team in demonstrating for the first time the ability of 2-bromo-LSD (BETR-001) to promote neural plasticity.